COV has superior specificity and sensitivity and is more progressed albeit for the pre-surgical indication vs general screening with hopefully FDA approval early next year . IIQ still requires large trials in the general population (and the associated $$) and FDA approvals.
Ignoring all that simply put head to head - sensitivity and specificity of 95% in COV and IIQ is 77%/95%
Ann: CLEO to Fast Track Development of Ovarian Cancer Test, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.030(8.11%) |
Mkt cap ! $32.64M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 40.0¢ | 37.0¢ | $33.65K | 86.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16950 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 26783 | 2 |
View Market Depth
| Last trade - 14.18pm 30/07/2025 (20 minute delay) ? |
| COV (ASX) Chart |